Clinical Trial Update: A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bilastine ophthalmic solution for allergic conjunctivitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• bilastine ophthalmic solution (bilastine)

Snippet

Sponsor: Faes Farma, S.A. | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-24